Cumberland Pharmaceuticals Inc. — FY2012 Form 10-K Summary
Business context and reporting period
Cumberland is a specialty pharmaceutical company focused on acquiring, developing and commercializing branded prescription products in hospital acute care and gastroenterology. Its marketed products are Acetadote, Caldolor and Kristalose; Hepatoren remains a Phase II candidate. The filing covers the fiscal year ended December 31, 2012. The filing also provides unaudited fourth-quarter results.
Key financial metrics
| Metric | 2012 | 2011 | Change |
|---|---|---|---|
| Net revenues | $48.9 million | $51.1 million | Down 4.5% |
| Net product revenues | $47.9 million | $50.9 million | Down 6% |
| Operating income | $8.8 million | $9.8 million | Down 10% |
| Net income attributable to common shareholders | $5.8 million | $5.7 million | Up 3% |
| Basic and diluted EPS | $0.30 | $0.28 | Up $0.02 |
| Cash flow from operations | $7.1 million | $8.7 million | Down 18% |
| Operating margin | 18.0% | 19.3% | Down 1.3 points |
| Net margin attributable to common shareholders | 12.0% | 11.1% | Up 0.9 points |
Net product revenue was led by Acetadote at $37.5 million, Kristalose at $9.4 million and Caldolor at $1.0 million. Acetadote revenue fell $4.9 million, while Kristalose increased $0.9 million and Caldolor increased $1.1 million. Other revenue increased to $0.9 million, primarily from a $0.7 million upfront payment under the China licensing agreement.
At December 31, 2012, cash and cash equivalents were $54.3 million, marketable securities were $16.7 million and total cash and marketable securities were approximately $71.0 million. Working capital was $79.2 million and the current ratio was 10.8x. Outstanding revolving credit was $4.4 million, with approximately $5.6 million of additional availability. Total assets were $98.6 million and total equity was $85.6 million.
Operating cash flow was positive, but investing activities used $19.2 million, primarily because the company invested $16.6 million in marketable securities. Financing activities used $4.2 million, including $8.1 million for share repurchases. The revolving credit facility carries a variable rate of LIBOR plus an applicable margin, reported at 2.21% at year-end, and matures December 31, 2014.
Material changes versus the prior comparable period
- Revenue declined primarily because Acetadote volumes normalized after elevated 2011 sales, including benefits from an oral N-acetylcysteine shortage.
- Caldolor revenue growth reflected higher volume and continued hospital-market penetration; the company focused domestically on the 800 mg offering after discontinuing the 400 mg offering.
- Cost of products sold declined to 10.3% of net revenues from 10.5% in 2011. Unlike 2011, the filing does not report a comparable $2.0 million inventory write-down in 2012.
- Selling and marketing expense decreased 3% to $20.3 million, despite approximately $0.7 million of sales-force realignment costs. Research and development increased 1% to $5.1 million, while general and administrative expense decreased 2% to $9.1 million.
- The effective tax rate decreased to 36% from 42%, primarily because of a deferred tax benefit related to the 2012 stock-option exchange program.
- The company reduced its national sales organization from 95 to 65 personnel and consolidated districts from 10 to 8 in November 2012.
- The company repurchased 1.27 million shares for approximately $8.1 million during 2012, reducing year-end shares outstanding to approximately 18.9 million from 20.0 million.
Guidance, outlook, commentary, risks and unusual items
No formal numerical revenue or earnings guidance is provided in the filing. Management states that internally generated cash flows and available credit are expected to fund existing debt service, internal growth and capital expenditures. Strategy remains focused on expanding the existing product portfolio, international licensing, additional product acquisitions and early-stage development through Cumberland Emerging Technologies.
- Hepatoren is in Phase II development for hepatorenal syndrome and has not been approved for marketing; its commercial prospects remain uncertain.
- Acetadote faces significant intellectual-property and generic-competition risk. The company received multiple Paragraph IV challenges, settled litigation with Paddock and Perrigo, and continued litigation with other parties and the FDA. Perrigo began distributing an authorized generic in January 2013.
- The FDA denied the company’s Citizen Petition seeking to restrict EDTA-containing acetylcysteine products, and InnoPharma received approval for a generic version of the older formulation.
- The company received a patent for the new Acetadote formulation expiring in May 2026 and a notice of allowance for a second patent expected to expire in August 2025, but the enforceability and commercial protection of these rights remain subject to litigation and regulatory developments.
- Manufacturing and distribution are outsourced. The company relies on limited suppliers, including a single primary supplier for each product, creating supply, quality, capacity and contract risks.
- Year-end Caldolor inventory was subject to expiration dates beginning in the second quarter of 2014, and the company had recognized approximately $2.6 million of potential obsolescence reserves, primarily for Caldolor.
- Three customers represented at least 10% of gross revenue each; together they represented approximately 93% of gross revenue in 2012, and 81% of accounts receivable at year-end.
- Sales-related accruals for rebates, returns, administrative fees and services increased to $3.4 million from $3.2 million. A one-percentage-point change in the product-return estimate could affect net sales by approximately $0.6 million.
- Contractual obligations totaled approximately $10.4 million, including $4.4 million of line-of-credit principal, $4.3 million of operating leases and $1.6 million of purchase obligations. Variable payments under the Kristalose purchase agreement are excluded because they depend on future sales.
Investor verification checklist
- Verify Acetadote volume trends, pricing, authorized-generic economics and the status and potential impact of remaining patent and FDA litigation.
- Assess whether Caldolor demand can absorb existing inventory before expiration and whether additional inventory charges may be required.
- Review customer concentration, wholesaler receivables and the assumptions supporting rebates, returns and chargeback accruals.
- Monitor Hepatoren clinical progress, regulatory milestones and future development spending.
- Confirm the company’s ability to refinance or repay the revolving credit facility at its December 2014 maturity and maintain compliance with covenants.
- Evaluate the effect of share repurchases, the sales-force reduction and international licensing arrangements on sustainable revenue growth.